A H Goldstone
- Pathology and Forensic Medicine top 2%
- Hematology top 2%
- Oncology top 10%
- Genetics top 5%
- Immunology
- Co-authors
- Norbert Claude GorinD MaraninchiRik SchotsThierry PhilipFranck ChauvinK. A. DickeJean‐Yves CahnJamés O. Armitage
- Topics
- Acute Myeloid Leukemia Research (8 papers)Acute Lymphoblastic Leukemia research (8 papers)Chronic Myeloid Leukemia Treatments (7 papers)
- Partner nations
- United KingdomSwitzerlandNetherlands
In The Last Decade
A H Goldstone
23 papers receiving 960 citations
Hit Papers
Peers
Comparison fields: 5 of 64
- Pathology and Forensic Medicine 502
- Hematology 406
- Oncology 405
- Genetics 245
- Immunology 178
Countries citing papers authored by A H Goldstone
This map shows the geographic impact of A H Goldstone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A H Goldstone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A H Goldstone more than expected).
Fields of papers citing papers by A H Goldstone
This network shows the impact of papers produced by A H Goldstone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A H Goldstone. The network helps show where A H Goldstone may publish in the future.
Co-authorship network of co-authors of A H Goldstone
This figure shows the co-authorship network connecting the top 25 collaborators of A H Goldstone. A scholar is included among the top collaborators of A H Goldstone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A H Goldstone. A H Goldstone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | REFINEMENT OF CYTOGENETIC CLASSIFICATION IN AML: DETERMINATION OF PROGNOSTIC SIGNIFICANCE OF RARE RECURRING CHROMOSOMAL ABNORMALITIES AMONGST 5635 YOUNGER ADULTS TREATED IN THE UK MRC TRIALS | 5 |
| 2 | Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 trial. | 1 |
| 3 | Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of the LRF AML14 trial | 4 |
| 4 | Refinement of cytogenetic classification in AML: determination of prognostic significance of rare recurring chromosomal abnormalities amongst patients entered into the UK MRC AML 10 & 12 trials. | 3 |
| 5 | Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993) | 21 |
| 6 | The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials. | 7 |
| 7 | Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial. | 8 |
| 8 | The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial. | 5 |
| 9 | Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993). | 1 |
| 10 | 70 | |
| 11 | 1 | |
| 12 | 13 | |
| 13 | Allo and auto BMT reduce relapse risk in AML in CR1 but do not significantly improve overall survival Results of the MRC AML 10 trial | 7 |
| 14 | A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial. | 13 |
| 15 | 7 | |
| 16 | Idarubicin for remission induction of acute myeloid leukemia: United Kingdom multicenter experience. | 9 |
| 17 | High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphomabreakdown → | 642 |
| 18 | 80 | |
| 19 | 6 | |
| 20 | 9 |
About A H Goldstone
A H Goldstone is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine, having authored 23 papers that have together received 1.0k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (8 papers), Acute Lymphoblastic Leukemia research (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). The work is most often cited by research in Hematology (406 citations), Pathology and Forensic Medicine (502 citations) and Genetics (245 citations). A H Goldstone has collaborated with scholars based in United Kingdom, Switzerland and Netherlands. Frequent co-authors include Norbert Claude Gorin, D Maraninchi, Rik Schots, Thierry Philip, Franck Chauvin, K. A. Dicke, Jean‐Yves Cahn, Jamés O. Armitage, Pierre Biron and Jean-Philippe Laporte. Their work appears in journals such as Nature, New England Journal of Medicine and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.